a treatment effectiveness study among sle patients receiving anifrolumab in routine clinical practice

Conditions: Systemic Lupus Erythematosus

Summary: anifrolumab study of treatment effectiveness in the real world (aster) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed sle patients who initiate anifrolumab treatment. aster will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for sle in routine clinical practice, to inform physicians, payers and patients.

aster is a multi-country, single-arm, prospective, observational study. the study will be initiated on a country-by country basis following the commercial launch of anifrolumab. aster is a cohort study, with 1-year retrospective baseline data and 3 years of follow-up data. the minimum enrolment period is anticipated to be 18 months per country and will be extended if necessary to reach the overall study target. in general, patients will enter the study between the first anifrolumab prescription and infusion (index), with follow-up until death, loss to follow-up, patient discontinuing the study, or end of study period (whichever occurs first). relevant clinical and patient-reported outcome (pro) data collection for the entire follow-up will continue for patients who have discontinued anifrolumab during the study, unless the patients have withdrawn their consent for participation in the study. the study will use clinical assessments that are relevant for sle-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating sle-related skin manifestations. the ecrfs will be accessed through secure web-based portals and will be used to ensure consistent data collection for each healthcare provider involved in this study. electronic data collection will be the only method of data collection in this study.

Eligibility criteria:
inclusion criteria: * fulfilled the 2019 eular (european league against rheumatism)/acr (american college of rheumatology) criteria for sle at the time of study entry. * prescribed anifrolumab for their sle treatment for the first time, according to approved country-specific label. * the physician's decision to prescribe anifrolumab must occur prior to any study-related discussion. * in countries where prescription reimbursements are authorised on a case-by-case basis, authorisation (ie, patient access to treatment) will be required for study entry. exclusion criteria: * currently participating in an anifrolumab early access/compassionate use program or an interventional clinical trial with an investigational product. * any previous exposure to anifrolumab (including as part of a clinical trial or early access programme). * documented diagnosis of severe or rapidly progressive class iii or iv glomerulonephritis requiring induction therapy (mycophenolate mofetil \[mmf\]/cyclophosphamide \[cyc\] + high dose steroids), isolated class v lupus nephritis (in absence of other sle manifestations, ie. skin/joint involvement), or active severe or unstable neuropsychiatric lupus. * any other condition which the investigator deems to limit a patient's ability to understand the informed consent.

Keywords: chronic autoimmune disease immunosuppressants corticosteroids human monoclonal antibody (igg1ƙ mab) real world